|Awarded On||August 21, 2019|
|Title||Advanced Cancer Antibody Drug Modalities Core Facility|
|Award Mechanism||Core Facility Support Awards|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Zhiqiang An|
|Cancer Sites||All Sites|
*Pending contract negotiation
Therapeutic antibodies have shown great success for treatment of cancer and other human diseases. Most antibody therapies currently in clinical use are conventional monoclonal antibodies. Because antibody therapeutics provides good safety profiles and target specificity, there is a trend toward development of advanced antibody drug modalities. These include antibodies linked to small molecule drugs (ADCs), bispecific antibodies and antibody fused to proteins, and antibody fragments (scFv) linked to T cell receptor complexes for use in CAR-T cell therapy. This core will provide innovative antibody engineering technologies for three key advanced antibody based drug modalities. One of the modal...